CGON
CGON clinical trials: CG Oncology, Inc.
Every trial on ClinicalTrials.gov where CG Oncology, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 8
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CGON on the catalyst calendar · CGON registry changes
- Primary completion Not registeredNo phase registeredNCT06443944An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGCG Oncology, Inc. · Non-Muscle Invasive Bladder CancerAvailableCGONLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2027Sponsor estimatePhase 2NCT06567743Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCCG Oncology, Inc. · High-Risk Non-Muscle-Invasive Bladder CancerRecruitingCGONLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2030Sponsor estimatePhase 3NCT04452591Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinCG Oncology, Inc. · Non Muscle Invasive Bladder CancerActive, not recruitingCGONLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 3NCT06111235A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTCG Oncology, Inc. · Non Muscle Invasive Bladder CancerActive, not recruitingCGONLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2015ActualPhase 2NCT02143804Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder CancerCG Oncology, Inc. · Bladder CancerWithdrawnCGONLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 7, 2023ActualPhase 2NCT04387461Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinCG Oncology, Inc. · Non Muscle Invasive Bladder CancerCompletedCGONLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2018ActualPhase 2NCT02365818Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG FailureCG Oncology, Inc. · Bladder CancerCompletedCGONLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2016ActualPhase 2/Phase 3NCT01438112Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder CancerCG Oncology, Inc. · Transitional Cell CarcinomaTerminatedCGONLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 25, 2024ActualPhase 1NCT04610671Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBCH. Lee Moffitt Cancer Center and Research Institute · Muscle-Invasive Bladder CarcinomaCompletedCGONCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner